Kevin C. Berryman
Analyst · JPMorgan
Thank you, Hernan. And good morning and good afternoon, everyone. Again, turning to our third quarter 2013 financial results, I would like to provide some additional insight into the trends that we are seeing in our business. Third quarter revenue totaled $742.3 million, an increase of 5% from the prior-year period. Excluding the impact of foreign currency, local currency sales increased 4%. Although the exit of low-margin sales activities were substantially completed in the second quarter of 2012, as Hernan earlier indicated, there remains some minor levels of sales for these activities in the third quarter of last year. As a result, if we adjust our results for these sales activities, our consolidated growth would've been 5% on a like-for-like basis, which puts us right in the middle of our long-term growth objectives. The overall growth reflects a balanced mix between our 2 business units, with Flavors growth of 3% and Fragrance growth of 5%, based on a continued, strong level of new wins across both business units. The emerging markets continue to perform well, up 8%, and they're up 9% year-to-date on a local currency basis. We believe the diversity we have in all 4 regions of the world and our investments in our organization will continue to fuel our long-term growth. We are very pleased with our strong momentum in all geographic regions, especially Western Europe, where Fine & Beauty Care delivered double-digit growth this quarter. The BRIC countries generated local currency sales growth of 9% and 14% for Fragrance Compounds. Local currency sales growth in China increased strong double digits for Fragrance Compounds as well. The developed markets also performed well, including France, which reported strong growth in Flavors and Fragrances. Adjusted gross margins for the quarter increased 170 basis points to 44.2% in the third quarter from the year-ago period as a result of moderating raw material costs combined with the strategic initiatives we have put in place to improve productivity. This is the sixth consecutive quarter of our gross margin expansion versus year ago. It is important to note that while we have recovered input cost so that gross profit has been protected the input cost pressure still represents a significant pressure point on our gross margins from pre-inflation levels. I will speak to this in a moment. One last note on our gross margins. Last quarter, we noted that we expected that the year-over-year margin improvement trend would begin to slow. We are beginning to see that play out as we are comparing margins to prior year levels that have already benefited from the margin enhancement efforts embedded in our strategic initiatives. Regarding operating expense investments, we continue to make investments in our R&D platforms to fuel our future growth. This quarter, as Nicolas mentioned, we made a milestone payment to Amyris, one of our biotechnology partners. These types of payments signify that key milestones are being met, and we are pleased with the progress we are making. We continue to believe that the output of this programs will provide us with dependable, competitive advantages. Adjusted operating profit for the quarter increased 7% to $144 million. As a result, adjusted operating profit margin increased 50 basis points to 19.4% in the quarter. On a year-to-date basis, our adjusted operating profit has increased 10%. Going further down the P&L. This quarter we realized modest foreign exchange gains on our working capital positions, reversing the losses we saw last quarter that where generated in those countries where we do not have hedging programs due to market conditions or other practical considerations. This reflects normal movements in currencies in those countries where hedging programs are problematic. Finally, our EPS for the quarter was $1.22, which was 13% ahead of the prior year. On a year-to-date basis, our EPS of $3.55 is 12% ahead of the prior year period, and we are pleased with our bottom line growth. By now you are probably familiar with this chart, which demonstrates that even though we are seeing margin gains of 170 basis points this quarter the net impact of historical rising input costs continues to be a headwind on our gross margins. If we look at the period Q3 2010 to Q3 2013, you will see the factors leading to the gross margin improvement between the 2 periods. Again, we chose the third quarter of 2010 as the base period since that is the last comparable quarter prior to the large increase in input costs that we saw in 2011 and 2012. Over the 3-year period, the net impact of our pricing actions and industry input cost increases has been a negative 160 basis points on our gross margins as evidenced by the red bar. It is important to note that we proactively worked with customers to implement pricing increases to reduce the strong pressure from input costs and limit the inflationary pressure to the 160 basis points noted on our slide. However, the importance of the execution of our strategy where we adopt the numerous measures to improve our margins, including the exit of low-margin sales activities, cost-savings initiatives, innovation enhancements, manufacturing efficiencies and restructuring and other gross margin improvement efforts, cannot be understated. These strategic improvements had a 350 basis point positive impact on our margins over the 3-year period as shown by the green bar on the chart. This more than offset the negative 160 basis point reduction from the net impact of input cost and pricing, resulting in our gross margins improving 190 basis points over the period. Turning to our RSA costs. RSA as a percent of sales increased to 120 basis points to 24.8%, up from 23.6% of sales in the prior year quarter. The higher RSA this quarter reflects higher incentive compensation accruals and higher R&D expenses versus year ago partially due to the previously mentioned milestone payment to Amyris in the Fragrance business. As we've mentioned in the past, strong performance versus budget in any quarter can lead to an increased compensation accrual through our AIP program. We accrue for these payouts on a quarterly basis, effectively matching the performance accrual to the performance in that specific quarter. In those quarters where we have strong sales and operating profit versus our expectations, we increase our accruals. Conversely, in those quarters where we fall short of performance expectations, we book smaller accruals, or even as we did in 2011, reversed previous accruals made. Importantly, including the incremental R&D costs and additional incentive compensation accruals, other RSA costs as a percent of sales, primarily sales and administrative expenditures, would've fallen 30 basis points as a percent of sales between Q3 of 2013 versus the comparable year-ago figure. It is important we remain disciplined in our approach to spending. And going forward, cost discipline will be a continued focus while strategically investing in R&D and other business development opportunities. Turning to foreign currency dynamics. Our foreign currency translation this quarter had 100 basis point positive impact on our reported sales. In addition, due to our proactive hedging activities with the euro, foreign currency had an immaterial impact on our operating profit results. As we have been communicating in 2013, we remain nearly 80% hedged against the euro at levels that approximate $1.29 per euro, effectively consistent with the average exchange rate levels for the full year 2012. At current rates, the operating impact on our full-year results is expected to continue to be muted. Importantly for 2014, we also have now hedged over 80% of our euro profit and cash flow exposure at $1.32 per euro. Turning to our cash flow. As you know, our business is very cash generative, and we are pleased with our improved operating cash flow performance this year. For the first 9 months of 2013, our operating cash flow was $257 million versus $138 million in the third quarter of 2012. However, there are some large items impacting our comparability that I would like to discuss. Number 1. Last year, we had a cash outflow of over $105 million related to our Spanish tax settlement. This outflow was included in our 2012 9-month year-to-date cash flow. Number 2, this year in the 9 months ended September 30, 2013, the company made an additional $30 million voluntary contributions to our qualified U.S. pension plans versus the 2012 comparable period. Finally, in the 9 months ended September 2013, the company paid out over $55 million in compensation payments based on the strong operating performance we had in 2012. In the first 9 months of 2012, our incentive compensation payments were less than $20 million, representative of the less-than-satisfactory performance that the company delivered in 2011 versus our internal objectives. If we exclude these items to make the year-over-year comparison more representative of our underlying operating cash flow trends, then the cash flow would've improved substantially from $263 million in the first 9 months of 2012 to $344 million in the first 9 months of 2013, or an increase of over $80 million. It is also worth noting that we accelerated our payment of our 2012 fourth quarter dividend into late December last year versus the normal planning of January of 2013. As a result, our 2013 year-to-date net cash flow has benefited as the first 9 months did not have the normally quarterly cash outflow associated with quarterly dividend payment in January. Turning to our capital structure. Early in the quarter, Standard & Poor's rating service raised its long-term corporate credit and senior secured debt issue ratings on IFF to BBB+ from BBB based our good operating performance and affirmed its A2 short-term corporate credit ratings. This brings S&P's ratings in line with Moody's. In July, we repaid $100 million of private placement notes from the proceeds of our $300 million public bond offering completed earlier in the year. The next material debt maturity is $125 million of private placement debt maturing in 2016, indicating that we continue to have significant financial flexibility. We are also making progress on our share buyback program. Through the end of the third quarter, we repurchased approximately 400,000 shares at an average price of $75 per share or approximately $33.4 million. Year-to-date through the end of October, we have spent a total of $42 million on buying back roughly 550,000 shares. We expect to meet our $50 million share repurchase goal for the year. With that, I would like to turn the call back to Doug to give a perspective on the balance of the year.